Fortune's David Ewing Duncan asks whether a "marriage between pharma and biotech will create more drugs." Pharmaceutical companies, he notes, "are struggling to replenish research development pipelines," whereas biotech firms "have the best ideas for new drugs but are constantly short of cash." But as of the Biotechnology Industry Organization meeting in Chicago last week, he says, the two are coming together.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.